A 36-year-old man presented 10 years ago with generalised lymphadenopathy and splenomegaly. A blood film revealed the presence of atypical cleaved small lymphocytes and bone marrow examination revealed a 50% lymphocytosis with deeply clefted lymphoid cells. Immunophenotype analysis of the marrow showed CD2 11%, CD3 5%, CD5 65%, CD19 63%, CD23 1%, FmC7 80%, CD10 1%, HLADr 51%, kappa 10%, lambda 80% strong. No cytogenetic abnormality was detected by metaphase analysis of the bone marrow. A lymph node biopsy confirmed the diagnosis of follicular lymphoma (REAL classification). Molecular analysis of the lymph node by PCR demonstrated the presence of the t(14;18) translocation at the major
breakpoint region (MBR). Treatment was commenced with chlorambucil (10 mg per day) with a complete response (CR). Seventeen months later a relapse occurred with lymphadenopathy and further treatment with chlorambucil (10 mg per day) produced a second CR.
Less than 2 years later, the patient had a third relapse of lymphoma with extensive lymphadenopathy, systemic B symptoms and widespread bone marrow infiltration with lymphoma. Bcl-2 staining of the trephine biopsy revealed a typical paratrabecular infiltrate with high levels of the protein. Combination (CHOP) chemotherapy was commenced (six courses) and clinically a partial response was achieved with only a persistent infiltrate of paratrabecular Bcl-2-positive cells in the bone marrow. A peripheral blood progenitor cell autograft with positive selection for CD34 ϩ cells was then performed. Conditioning with cyclophosphamide 60 mg/kg for 2 days and total body irradiation 1440 cGy in eight fractions over 4 days was used in preparation. Post autograft low dose interferon (3 Mega Units, three times a week) maintenance therapy was initiated.
The disease relapsed again with follicular lymphoma 12 months after the transplant. The interferon was discontinued and chlorambucil (10 mg per day) was restarted. A complete remission was achieved, but a further relapse was noted 5 months later. Chlorambucil therapy (10 mg per day) was recommenced but the disease response was minimal and therapy was changed to fludarabine with cotrimoxazole prophylaxis. A generalised pruritic rash developed which failed to settle upon stopping the co-trimoxazole. A bone marrow examination was performed and a diagnosis of Phϩ T cell ALL was made and confirmed by conventional cytogenetics and immunophenotyping. This consisted of predominantly TdT-positive lymphoblasts expressing CD7, HLADr, CD2, CD5 (CD3 7%, CD7 87%, CD10 81%, CD11c 11%, CD13 5%, CD33 7%, CD14 Ͻ1%, CD19 5%, CD34 84%, HLADr 81%, CD2 75%, CD5 70%). Acute lymphoblastic leukaemia therapy consisting of vincristine, daunorubicin, prednisolone, asparaginase and intrathecal methotrexate was initiated. The neutropenic phase of his treatment response was complicated by respiratory Aspergillus infection which was treated with liposomal amphotericin. Bone marrow examination confirmed a partial response to the first course of treatment but the majority of cells remained Phϩ. The leukaemia failed to respond to further treatment and the patient died 4 weeks later.
Results of molecular analysis
DNA from the initial lymph node biopsy was examined for the presence of a clonal marker. IgH PCR using the framework III and consensus Ig JH primers revealed a monoclonal population of cells compatible with a B cell lymphoma (Figure 1 ), but was negative for the presence of the TCR ␥ receptor as determined by PCR. The same sample also showed the presence of a t(14;18) with a breakpoint at the major breakpoint region (MBR) by PCR. Similar studies on the bone marrow following the diagnosis of T-ALL showed a lack of clonal IgH rearrangement and no t(14;18) translocation, but did reveal a clonal population of cells as determined by the TCR ␥ PCR. The Philadelphia chromosome was also detected cytogenetically in the T-ALL marrow, with no evidence of the BCR/ABL fusion in the lymph node (Figure 2 ).
Discussion
T cell malignancies arising from the background of a follicular B cell lymphoma are rare, but do occur. However, these have all been in the form of lymphoma.
1,2 We describe a T cell ALL arising in a patient with documented FL. Molecular analysis confirms the diagnosis, lineage and clonality of both the lymphoma and leukaemia. It has previously been suggested that the genetic event leading to FL occurs very early in the lymphoid stem cell lineage 2 from a common single cell of origin, prior to commitment to B or T cell development. These findings further support this hypothesis. Phϩ T-ALL itself is a rare event. 3 Westbrook et al 3 concluded that BCR-ABL positive T-ALL was uncommon (less than 6%) and was not seen in patients who did not co-express B cell markers. The patient described expressed only clonal T cell markers (PCR evidence) together with the cytogenetically detected Philadelphia chromosome. PCR data confirmed the development of a new malignant clone (which had been previously undetectable) without a trace of the original t(14;18) B cell clone.
There exists the possibility that the second malignancy developed as a direct consequence of treatment with alkylating agents and/or purine analogues. However, ther- apy-related haemopoietic disease generally manifests as acute myeloid leukaemia or myelodysplasia with the risk being highest in the 5-9-year follow-up period. 4 The predominant cytogenetic abnormalities found in therapyrelated leukaemias occur on chromosomes 5q, 7q and 11q23 (usually following treatment with topoisomerase II inhibitors). 4 Therapy-related ALL is rare, but has been described. 4 In the reported cases rearrangements of the MLL gene on chromosome 11q23 are frequently involved; the presence of the Philadelphia chromosome is extremely unusual, 4, 5 and only a handful of cases have ever been reported. 6 In this case both the time course and type of genetic abnormalities suggest that this is not a therapyrelated leukaemia.
The underlying cause of this patient's disease could be explained by a predisposition to DNA alteration, which in turn leads to an inherent predisposition to haematological malignancy. It is possible that this patient had inherited a deficiency in DNA repair, whereby treatment with chemotherapy can induce DNA damage (either by causing double strand breaks or damage to individual bases), which can in turn lead to oncogene activation. Evidence is already present that follicular lymphomas are genetically unstable. The presence of the t(14;18) translocation leads to excessive Bcl-2 expression and a failure of apoptosis. This acts as a permissive event for further genetic abnormalities to occur as often seen in transforming follicular lymphoma with additional 1q, 6q, ϩ7, ϩ12 and chromosome 8 (cmyc) abnormalities. 7, 8 De novo B cell ALL with t(14;18) is unusual, but has a poor prognosis and again it is thought that the t(14;18) is the predisposing event for further genetic change. 9 Transgenic mice with t(14;18) add further evidence to this hypothesis. 10 However the development of genetic changes and second malignancy (eg T cell lymphoma, AML) without the t(14;18) translocation in patients with previously diagnosed t(14;18)-positive follicular lymphoma suggests a more fundamental defect in genomic stability in the predisposed early lymphoid committed stem cell. Furthermore, this defective stem cell has the ability to develop into a range of lymphoid malignancies. In addition the t(14;18) translocation in follicular lymphoma may often arise on the background of genetically unstable committed stem cells prior to the development of the t(14;18) translocation. Follicular lymphoma is essentially incurable by conventional therapy and this may be due largely to the basic instability of the disease cell as demonstrated by this case.
This report reveals at clinical, pathological and molecular levels the development of two distinct haematological malignancies. It also suggests that patients with follicular lymphoma may be a group who have inherently unstable DNA at an early pre-B or pre-T cell stage of development.
